Evidence map›Paper›PMID 38608332›Full record

ArticleHearing research2024

L-Ergothioneine slows the progression of age-related hearing loss in CBA/CaJ mice.

Mark A Bauer, Parveen Bazard, Alejandro A Acosta, Nidhi Bangalore, Lina Elessaway, Mark Thivierge, Moksheta Chellani, Xiaoxia Zhu, Bo Ding, Joseph P Walton and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hearing research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. King Oyster Mushroom,Nutrients · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Mark A BauerDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Parveen BazardDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA. Electronic address: parveen1@usf.edu.
Alejandro A AcostaSchool of Medicine, University of Puerto Rico, San Juan, 00925 Puerto Rico; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Nidhi BangaloreDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Lina ElessawayDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Biomedical Sciences - Dept. of Chemistry, University of South Florida, Tampa, FL 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Mark ThiviergeDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Moksheta ChellaniDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Xiaoxia ZhuDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Bo DingDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Joseph P WaltonDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Department Communication Sciences and Disorders, College of Behavioral & Community Sciences, Tampa, FL 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA.
Robert D FrisinaDepartment of Medical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33620, USA; Department Communication Sciences and Disorders, College of Behavioral & Community Sciences, Tampa, FL 33620, USA; Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA; Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL 33612, USA. Electronic address: rfrisina@usf.edu.
University of South Florida · USUniversity of Puerto Rico System · PR

Funding

Structure and Function Services CoreP01AG009524 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI FRISINA, ROBERT D · 1992 to 2021
$23.2M
Sex Effects for Hearing Loss Drug TherapiesR21DC021546 · NIDCD · UNIVERSITY OF SOUTH FLORIDA · PI BAZARD, PARVEEN, FRISINA, ROBERT D · 2023 to 2023
$413k
Elucidation of Under-Investigated Biological Mechanisms of Age-Related Hearing LossR21DC017039 · NIDCD · UNIVERSITY OF SOUTH FLORIDA · PI FRISINA, ROBERT D · 2019 to 2020
$411k
NIA NIH HHS P01 AG009524NIDCD NIH HHS R21 DC017039NIDCD NIH HHS R21 DC021546
6 · The paper itself

Abstract

The naturally occurring amino acid, l-ergothioneine (EGT), has immense potential as a therapeutic, having shown promise in the treatment of other disease models, including neurological disorders. EGT is naturally uptaken into cells via its specific receptor, OCTN1, to be utilized by cells as an antioxidant and anti-inflammatory. In our current study, EGT was administered over a period of 6 months to 25-26-month-old CBA/CaJ mice as a possible treatment for age-related hearing loss (ARHL), since presbycusis has been linked to higher levels of cochlear oxidative stress, apoptosis, and chronic inflammation. Results from the current study indicate that EGT can prevent aging declines of some key features of ARHL. However, we found a distinct sex difference for the response to the treatments, for hearing - Auditory Brainstem Responses (ABRs) and Distortion Product Otoacoustic Emissions (DPOAEs). Males exhibited lower threshold declines in both low dose (LD) and high dose (HD) test groups throughout the testing period and did not display some of the characteristic aging declines in hearing seen in Control animals. In contrast, female mice did not show any therapeutic effects with either treatment dose. Further confirming this sex difference, EGT levels in whole blood sampling throughout the testing period showed greater uptake of EGT in males compared to females. Additionally, RT-PCR results from three tissue types of the inner ear confirmed EGT activity in the cochlea in both males and females. Males and females exhibited significant differences in biomarkers related to apoptosis (Cas-3), inflammation (TNF-a), oxidative stress (SOD2), and mitochondrial health (PGC1a).These changes were more prominent in males as compared to females, especially in stria vascularis tissue. Taken together, these findings suggest that EGT has the potential to be a naturally derived therapeutic for slowing down the progression of ARHL, and possibly other neurodegenerative diseases. EGT, while effective in the treatment of some features of presbycusis in aging males, could also be modified into a general prophylaxis for other age-related disorders where treatment protocols would include eating a larger proportion of EGT-rich foods or supplements. Lastly, the sex difference discovered here, needs further investigation to see if therapeutic conditions can be developed where aging females show better responsiveness to EGT.

Indexed as

AgingAntioxidantsCochleaDisease Models, AnimalDisease ProgressionErgothioneineEvoked Potentials, Auditory, Brain StemMice, Inbred CBAOxidative StressPresbycusisAge FactorsAnimalsAnti-Inflammatory AgentsApoptosisAuditory ThresholdFemaleAnti-Inflammatory AgentsAntioxidantsErgothioneineSuperoxide DismutaseAge-related hearing lossAuditory brainstem responses (ABRs)Distortion product otoacoustic emissions (DPOAEs)ErgothioneineMiceReverse transcriptase polymerase chain reaction (RT-PCR)Sex selectivity

Identifiers

PMID38608332
PMCPMC11112832
OpenAlexW4393408912

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.